Lipid nanoparticles (LNPs) have emerged as promising vehicles to deliver a variety of therapeutics in the pharmaceutical industry. Liposomal drugs, based on an earlier version of LNPs, have already been approved and applied to medical practice. LNPs have the ability to encapsulate and deliver therapeutics to specific locations in the body and release their contents at a specific time, which makes them desired platforms for further drug usage.
In this peer-reviewed article published in ACS Nano, the landscape of LNP-related publications in the CAS Content Collection is examined in detail. Also discussed are growth opportunities for LNP usage in the fields of antitumor therapeutics, nucleic therapeutics, and vaccine delivery systems, as well as the potential challenges of utilizing the material. Read the full publication here.
